| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AstraZeneca) D926PC00001 / TROPION-Breast02 | A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Dr Louise Bordeleau | Open to recruitment | NCT05374512 |
| (CCTG) MA.39 / TAILOR RT | A randomized trial of regional radiotherapy in Biomarker low risk node positive breast cancer (TAILOR RT) | Dr Timothy Whelan | Open to recruitment | NCT03488693 |
| (CCTG) MA.40 / FINER | A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT04650581 |
| (Roche) WO43919 / INAVO121 | A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant In Patients With Hormone Receptor positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During Or After CDK4/6 Inhibitor and Endocrine Combination Therapy. | Dr Haider Samawi | Suspended/On hold | NCT05646862 |
| OCOG-2019-RHEAL | Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL) | Dr Timothy Whelan | Open to recruitment | NCT04228991 |
| OCOG-2021-ELISA | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study) | Dr Timothy Whelan | Open to recruitment | NCT04797299 |
Find a Trial
Contact Us